Victory Capital Management Inc. Boosts Stake in Sanofi (NASDAQ:SNY)

Victory Capital Management Inc. raised its position in Sanofi (NASDAQ:SNY) by 27.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,669 shares of the company’s stock after buying an additional 1,876 shares during the period. Victory Capital Management Inc.’s holdings in Sanofi were worth $500,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. Tidal Investments LLC purchased a new stake in shares of Sanofi during the 1st quarter worth approximately $228,000. Atria Investments Inc increased its stake in shares of Sanofi by 31.1% during the 1st quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after purchasing an additional 23,463 shares during the last quarter. Cetera Investment Advisers increased its stake in shares of Sanofi by 245.4% during the 1st quarter. Cetera Investment Advisers now owns 178,349 shares of the company’s stock worth $8,668,000 after purchasing an additional 126,712 shares during the last quarter. Cetera Advisors LLC increased its stake in shares of Sanofi by 301.6% during the 1st quarter. Cetera Advisors LLC now owns 60,359 shares of the company’s stock worth $2,933,000 after purchasing an additional 45,330 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Sanofi by 44.5% during the 2nd quarter. GAMMA Investing LLC now owns 3,063 shares of the company’s stock worth $149,000 after purchasing an additional 944 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Down 0.5 %

SNY opened at $48.49 on Friday. The company has a 50 day moving average of $52.80 and a 200 day moving average of $52.11. The company has a market cap of $123.06 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.61. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same period last year, the firm earned $2.55 EPS. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, sell-side analysts expect that Sanofi will post 4.29 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.